BioCryst Pharmaceuticals BCRX Foreign currency translation
Foreign currency translation at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's foreign currency translation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's foreign currency translation?
- BioCryst Pharmaceuticals (BCRX) reported foreign currency translation of -$62K in Q1 2026.
- How has BioCryst Pharmaceuticals's foreign currency translation changed year-over-year?
- BioCryst Pharmaceuticals's foreign currency translation decreased by 116.9% year-over-year, from $366K to -$62K.
- What is the long-term trend for BioCryst Pharmaceuticals's foreign currency translation?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's foreign currency translation has grown at a 37.4% compound annual growth rate (CAGR), from $189K to -$674K.
- What does foreign currency translation mean?
- The net change in equity resulting from the translation of financial statements of foreign subsidiaries from their functional currency into the reporting currency. It captures the impact of exchange rate movements on the value of international assets and liabilities.